Cancer immunogenicity, danger signals, and DAMPs: What, when, and how?
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Cancer immunosurvelliance usually leads to formation of cancer cells that have been “immunoedited” to resist anti‐tumor immunity. One of the consequences of immunoediting that is, reduced immunogenicity, is an important roadblock in revival of stable and long‐lasting anti‐tumor immune responses. Research done during the last decade has shown that emission by the dying cancer cells of immunomodulatory factors or damage‐associated molecular patterns (DAMPs), which can act as danger signals, is a critical event in accentuating the immunogenicity of cancer cells, in response to a subset of anticancer treatments. Recent evidence has defined that an apoptotic cell death subroutine and its underlying biochemistry, which has been termed as “immunogenic cell death (ICD)” or “immunogenic apoptosis,” is required for the efficient emission of DAMPs and inciting anti‐tumor immunity. Here, we review the basic concepts of ICD, like cancer immunogenicity, danger signals, and DAMPs. Moreover, we discuss the emerging molecular links between endoplasmic reticulum (ER) stress, induction of a viral response‐like gene expression, danger signals, and anti‐tumor immunity. We envisage that along with ER stress‐based trafficking of DAMPs (which is a “short‐range communicator” of danger), the accompanying induction of a viral response‐like gene expression and the secretion of anti‐tumorigenic cytokines may become a crucial signature of ICD induction by anticancer therapy. © 2013 BioFactors, 39(4):355–367, 2013
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981 · cited 1×
“This is because in most cases, Th1 cells and IFN-c production rather than Th2 cells and IL-10 production (in tumors) have been found to strongly associate with positive clinical outcomes in cancer patients [57].”
BackgroundThe Danger Model: A Renewed Sense of Self
Matzinger, P. (2002) · Science · doi:10.1126/science.1071059 · Cited by 4,205
Circulating mitochondrial DAMPs cause inflammatory responses to injury
Zhang, Q., Raoof, M., Chen, Y., Sumi, Y., Sursal, T., Junger, W., Brohi, K., Itagaki, K., & Hauser, C. J. (2010) · Nature · doi:10.1038/nature08780 · Cited by 3,812
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303 · cited 9×
“It is well established now that in order to activate potent anti-tumor immunity (as happens in the case of ICD [5,25,27,33]), DAMPs-based immunogenicity is required to establish a dying cancer cell-DC interface (preferably consisting of TLR stimulation and devoid of immunosuppressive factors like IL-10) that ultimatel…”
BackgroundInfluentialImmunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Self-citationCalreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216 · cited 7×
“Pre-apoptotic DAMP trafficking: The most described preapoptotic DAMP trafficking event is the surface exposure of CRT (by anthracyclines [32], oxaliplatin [92], UVC [93], ionizing-irradiation [93–95], 7A7 [96], cyclophosphamide [5,28], Hyp-PDT [24,33,51], CVB3 [97]).”
BackgroundInfluentialFadok, V. A., Bratton, D. L., Konowal, A., Freed, P. W., Westcott, J. Y., & Henson, P. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1112 · Cited by 3,166 · cited 5×
“Ability to induce immunotolerance or active immunosuppression: through immunosuppressive cytokines like IL-10 [8,9] or transforming growth factor-beta (TGF-b) [10,11]; or expression of immune cell checkpoint ligands that inhibit anti-tumor immunity [12]; 3.”
BackgroundInfluentialApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 4×
“Various immune cells like the natural killer (NK) cells, dendritic cells (DCs), and T cells actively participate in recognition and elimination of such newly formed immunogenic neoplastic cells during this phase [2,3].”
BackgroundInfluentialDAMPs, PAMPs and alarmins: all we need to know about danger
Bianchi, M. E. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0306164 · Cited by 2,794
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 1×
“Moreover, different tumors may exhibit immunosuppressive abilities unique to each tumor type for example, while some tumor types may produce immunosuppressive cytokines (mentioned above), yet others may produce enzymes like indoleaminepyrrole-2,3-dioxygenase or tryptophan-2,3dioxygenase [20,21] for immunoevasion.”
BackgroundGhiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Opitz, C. A., Litzenburger, U. M., Sahm, F., Ott, M., Tritschler, I., Trump, S., Schumacher, T., Jestaedt, L., Schrenk, D., Weller, M., et al. (2011) · Nature · doi:10.1038/nature10491 · Cited by 1,898
Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance
Elliott, M. R., Chekeni, F. B., Trampont, P. C., Lazarowski, E. R., Kadl, A., Walk, S. F., Park, D., Woodson, R. I., Ostankovich, M., Sharma, P., et al. (2009) · Nature · doi:10.1038/nature08296 · Cited by 1,654 · cited 1×
“Nevertheless, it is interesting to note that despite the above differences, ATP secreted in both pannexin-1-dependent or autophagy-dependent fashion has been found to rely on the activity of the caspases [99,107].”
BackgroundCaspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512 · cited 4×
“Various immune cells like the natural killer (NK) cells, dendritic cells (DCs), and T cells actively participate in recognition and elimination of such newly formed immunogenic neoplastic cells during this phase [2,3].”
BackgroundInfluentialAutophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. (2011) · Science · doi:10.1126/science.1208347 · Cited by 1,377
Cancer despite immunosurveillance: immunoselection and immunosubversion
Zitvogel, L., Tesniere, A., & Kroemer, G. (2006) · Nature reviews. Immunology · doi:10.1038/nri1936 · Cited by 1,324 · cited 7×
“In this scenario, the immune system starts acting as a selection force that actively eliminates the “residual” highly immunogenic cancer cells while exhibiting inability in controlling the “clonal expansion” of the low immunogenic cancer cells [2,3,5].”
BackgroundInfluentialPannexin 1 channels mediate ‘find-me’ signal release and membrane permeability during apoptosis
Chekeni, F. B., Elliott, M. R., Sandilos, J. K., Walk, S. F., Kinchen, J. M., Lazarowski, E. R., Armstrong, A. J., Penuela, S., Laird, D. W., Salvesen, G. S., et al. (2010) · Nature · doi:10.1038/nature09413 · Cited by 1,120
Mechanisms of pre‐apoptotic calreticulin exposure in immunogenic cell death
Panaretakis, T., Kepp, O., Brockmeier, U., Tesniere, A., Bjorklund, A., Chapman, D. C., Durchschlag, M., Joza, N., Pierron, G., van Endert, P., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.1 · Cited by 848 · cited 17×
“Our analysis showed that caspase-8 (important for chemotherapy-induced ecto-CRT and immunogenicity [33,72]) and BAX (important for chemotherapy and Hyp-PDT induced ecto-CRT and immunogenicity [33,72]) were two such proteins, involved in cell death signaling and DAMP trafficking, which were highly susceptible to inacti…”
BackgroundInfluentialA novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death
Garg, A. D., Krysko, D. V., Verfaillie, T., Kaczmarek, A., Ferreira, G. B., Marysael, T., Rubio, N., Firczuk, M., Mathieu, C., Roebroek, A. J. M., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2011.497 · Cited by 800 · cited 9×
“It is well established now that in order to activate potent anti-tumor immunity (as happens in the case of ICD [5,25,27,33]), DAMPs-based immunogenicity is required to establish a dying cancer cell-DC interface (preferably consisting of TLR stimulation and devoid of immunosuppressive factors like IL-10) that ultimatel…”
BackgroundInfluentialSelf-citationCD24 and Siglec-10 Selectively Repress Tissue Damage–Induced Immune Responses
Chen, G.-Y., Tang, J., Zheng, P., & Liu, Y. (2009) · Science · doi:10.1126/science.1168988 · Cited by 786 · cited 2×
“In fact, DAMPs (like HMGB1, HSP70, and HSP90) but not PAMPs (like LPS) engage the CD24-Siglec G/10 surface protein complex on immune cells, which subsequently suppresses immune response as reflected by the decrease in NF-kB activation [56].”
BackgroundGobert, M., Treilleux, I., Bendriss-Vermare, N., Bachelot, T., Goddard-Leon, S., Arfi, V., Biota, C., Doffin, A. C., Durand, I., Olive, D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2360 · Cited by 758
Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation
Krysko, D. V., Agostinis, P., Krysko, O., Garg, A. D., Bachert, C., Lambrecht, B. N., & Vandenabeele, P. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.01.005 · Cited by 680 · cited 2×
“The actual diversity and nature of DAMPs released after stress/damage depends strongly on various factors for example, type of cell death sub-routine, type of physical or chemical stress, chemistry of cellular stress response pathways, cancer cell type, and the nature of tissue injury [3,5,25,29,46,47].”
BackgroundSelf-citationInside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox
Rubartelli, A., & Lotze, M. T. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.08.004 · Cited by 614 · cited 15×
“DAMPs/danger signals have the ability to [3,5,29,46]: 1) activate immune cells like the DCs, macrophages, certain T cells, NK cells (Fig.”
BackgroundInfluentialDecoding Cell Death Signals in Inflammation and Immunity
Zitvogel, L., Kepp, O., & Kroemer, G. (2010) · Cell · doi:10.1016/j.cell.2010.02.015 · Cited by 558 · cited 2×
“ATP P2Y2 and P2X7 Secreted during ICD via a pathway involving ER stress response, classical secretory pathway or autophagy and caspase signaling or pannexins and caspase signaling, in an inducer-dependent fashion; released passively during necrosis and secondary necrosis; [35,37]”
BackgroundObeid, M., Panaretakis, T., Joza, N., Tufi, R., Tesniere, A., van Endert, P., Zitvogel, L., & Kroemer, G. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402201 · Cited by 474 · cited 2×
“ICD inducers that can evoke ER stress in this manner include cardiac glycosides, UVC treatment, and wogonin [5,24,28,81–83].”
BackgroundAn Immunosurveillance Mechanism Controls Cancer Cell Ploidy
Senovilla, L., Vitale, I., Martins, I., Tailler, M., Pailleret, C., Michaud, M., Galluzzi, L., Adjemian, S., Kepp, O., Niso-Santano, M., et al. (2012) · Science · doi:10.1126/science.1224922 · Cited by 436
Spisek, R., Charalambous, A., Mazumder, A., Vesole, D. H., Jagannath, S., & Dhodapkar, M. V. (2007) · Blood · doi:10.1182/blood-2006-10-054221 · Cited by 388 · cited 3×
“Also, the proteasome-inhibitor, Bortezomib, has been known for a long time to be potent inducer of ICD and DAMP trafficking (especially ecto-HSP90) [102].”
BackgroundThe co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death
Panaretakis, T., Joza, N., Modjtahedi, N., Tesniere, A., Vitale, I., Durchschlag, M., Fimia, G. M., Kepp, O., Piacentini, M., Froehlich, K.-U., et al. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.67 · Cited by 344
ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death
Garg, A. D., Dudek, A. M., Ferreira, G. B., Verfaillie, T., Vandenabeele, P., Krysko, D. V., Mathieu, C., & Agostinis, P. (2013) · Autophagy · doi:10.4161/auto.25399 · Cited by 305
Self-citationPhotodynamic therapy: illuminating the road from cell death towards anti-tumour immunity
Garg, A. D., Nowis, D., Golab, J., & Agostinis, P. (2010) · Apoptosis · doi:10.1007/s10495-010-0479-7 · Cited by 297 · cited 1×
“ATP P2Y2 and P2X7 Secreted during ICD via a pathway involving ER stress response, classical secretory pathway or autophagy and caspase signaling or pannexins and caspase signaling, in an inducer-dependent fashion; released passively during necrosis and secondary necrosis; [35,37]”
BackgroundSelf-citationCD24-Siglec G/10 discriminates danger- from pathogen-associated molecular patterns
Liu, Y., Chen, G.-Y., & Zheng, P. (2009) · Trends in Immunology · doi:10.1016/j.it.2009.09.006 · Cited by 147 · cited 1×
“DAMPs trigger a relatively modest autoimmunity reaction thereby implying that the host immune system might be able to differentiate between DAMPs and PAMPs on a certain level so as to “control” inflammation in response to DAMPs [55].”
BackgroundGarrido, G., Rabasa, A., Sánchez, B., López, M. V., Blanco, R., López, A., Hernández, D. R., Pérez, R., & Fernández, L. E. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003477 · Cited by 91
Cited by
Consensus guidelines for the detection of immunogenic cell death
Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., Apetoh, L., Aranda, F., Barnaba, V., Bloy, N., et al. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955691 · Cited by 832
Self-citationPhotodynamic therapy in cancer treatment - an update review
Dos Santos, A. F., De Almeida, D. R. Q., Terra, L. F., Baptista, M. S., & Labriola, L. (2019) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2018.83 · Cited by 446
Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses
Garg, A. D., & Agostinis, P. (2017) · Immunological Reviews · doi:10.1111/imr.12574 · Cited by 440
Self-citationMolecular and Translational Classifications of DAMPs in Immunogenic Cell Death
Garg, A. D., Galluzzi, L., Apetoh, L., Baert, T., Birge, R. B., Bravo-San Pedro, J. M., Breckpot, K., Brough, D., Chaurio, R., Cirone, M., et al. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00588 · Cited by 410
Self-citationDudek, A. M., Martin, S., Garg, A. D., & Agostinis, P. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00438 · Cited by 399
Self-citation
Metadata
- Authors
- Garg, A. D., Dudek, A. M., & Agostinis, P.
- Venue
- BioFactors
- Publisher
- Wiley
- Published
- 2013-07
- Volume
- 39
- Issue
- 4
- Pages
- 355-367
- ISSN
- 0951-6433 (ISSN-L)
- 1872-8081
- OpenAlex
- W1530610894
- Cited by
- 108
- References
- 33
- FWCI
- 6.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.